Sponsored Satellite Symposia

 

Thursday April 12th

PRE CONFERENCE WORKSHOP:

Integrated Personalized Diabetes Management: jointly rethinking current routines in daily clinical practice (Pre-registration required)

Sponsored by:

17:00 - 17:30

Lecture
Speaker: Prof. Dr. Bernhard Kulzer
Head of Psychosocial Department, Diabetes Clinic.
Mergentheim, Germany

17:30 - 19:00

Co-creation session
Participants form groups of 6 in round tables 
Role-play

Abstract
How can the potential of personalized diabetes management and digital tools be mobilized to serve patients, health care professionals and the care process and facilitate improved outcomes? How can we address clinical inertia – the failure to reach individualized therapeutic goals in a timely manner -for people with type 2 diabetes? We think we have found a clue to these questions in the results of our PDM-ProValue study program, which investigated the potential benefit of integrated personalized diabetes management (iPDM) for the treatment of patients with insulin-treated type 2 diabetes.

iPDM is an interventional approach consisting of a structured, 6-step process which integrates digital tools and, by its set up, intends to bring together physicians and patients for collaborative, therapeutic decision-making. Basically, the process allows to agree upon personalized diagnostics and treatment schemes which are closely documented, assessed and monitored in an iterative way.

In this co-creation session we want to mutually explore new approaches that could leverage personalized diabetes management in daily clinical routine.

 



Friday April 13th


LUNCH SATELLITE SYMPOSIUM:

Supporting patients facing barriers to insulin therapy in everyday clinical practice

Sponsored by:


This symposium is partially sponsored by the Boehringer Ingelheim and Eli Lilly Diabetes Alliance


AGENDA

13:00 Introduction. Opening Remarks
13:15 Clinical Case Discussion: Clinical Perspectives from a Primary Care Physician and Psychologist
14:05 Panel Discussion
14:20 Closing Remarks

SPEAKERS
Professor Frank J. Snoek, Phd
Professor Pinar Topsever, MD

SYMPOSIUM LEARNING OBJECTIVES
Through attending this Type 2 diabetes case-based session, you should be able to:

  • Understand the emotional barriers to initiating insulin therapy
  • Address patient concerns to help overcome emotional barriers and encourage insulin acceptance and adherence
  • Optimise discussions around hypoglycaemia, particularly with individuals who are reluctant to start insulin
  • Understand key steps that ensure a positive start on insulin therapy

Conference Flyer
Download the original conference flyer here.

 



Friday April 13th

AFTERNOON SATELLITE SYMPOSIUM:

OPTIMIZING TREATMENT FOR TYPE 2 DIABETES PATIENTS: Understanding Hypoglycaemia, Cardiovascular Outcomes Trials, and Combination Therapies to Improve Better Patient Care

Sponsored by:


SYMPOSIUM FORMAT AND LEARNING OBJECTIVES
This aim of this educational initiative is to educate the primary care physicians on the risks of hypoglycemia to the type 2 diabetes patient as well as present how the results of recent clinical trials demonstrate the cardiovascular benefits of long-acting insulin therapy. Recent studies clearly show a significant relationship between day-to-day fasting glucose excursions and glycemic variability, severe hypoglycemia, and all-cause mortality. With this information, the primary care physicians will be better able to identify at-risk patients and provide appropriate, evidence-based treatment upon the conclusion of this educational activity.

The following key topics will be covered in the symposium presentations:

  • Hypoglyaemia etiology and risk in type 2 diabetes
  • The impact of hypoglycaemia on patient outcomes and functioning
  • Evidence for decreased cardiovascular risk with newer diabetes therapies
  • Insulin therapy and glyacemic variability
  • Combined insulin and GLP-1 RA therapy

In specific, the symposium will strive to address the following learning objectives:

  • Discuss the CV benefits associated with new type 2 diabetes (T2D) drugs and insulin formulations, including new injectable therapy options (insulin + glucagon-like peptide 1 receptor agonists [GLP-1 RAs])
  • Understand current evidence on the association between glycaemic variability, hypoglycaemia, and CV risk
  • Identify patients at risk and ensure that appropriate treatment plan changes are put in place


OPTIMIZING TREATMENT FOR TYPE 2 DIABETES PATIENTS:
Understanding Hypoglycaemia, Cardiovascular Outcomes Trials, and Combination Therapies to Improve Better Patient Care

Program Speakers:
 
Program Chair: Andrew J.M. Boulton, MD
President, Board of Directors
Worldwide Initiative for Diabetes Education
Professor of Medicine
University of Manchester Manchester, United Kingdom

Program Speakers:
Francesc Xavier Cos, MD
Head of Innovation and Health in Primary Care City of Barcelona
Barcelona, Spain

Brian Frier, MD, FECP, BS
Honorary Professor of Diabetes
The Queen’s Medical Research Institute
University of Edinburgh
Edinburgh, United Kingdom

Kamlesh Khunti, PhD, MD, FRCGP, FRCP
Professor of Primary Care Diabetes and Vascular Medicine
Senior Investigator, National Institute of Health Research
Diabetes Research Centre
Leicester, United Kingdom

AGENDA

Time Presenter/facilitator  Session 
17:00     Registration and Snack Service
17:15   Andrew Boulton, MD Welcome, Introductions, and Objectives
17:30  Xavier Cos, MD 

Insights from Recent Cardiovascular Outcomes
Trials in Diabetes

17:55 Brian Frier, MD    The Association Between Glycaemic Variability, Hypoglycaemia and Outcomes
18:20 Kamlesh Khunti, MD    Fixed Ratio Combination Therapies of Insulin and GLP-1 Receptor Agonists:  For Whom and When
18:45  All Faculty    PANEL DISCUSSION: QUESTION AND ANSWER SESSION
19:00    Andrew Boulton, MD Wrap up




Technical Secretariat:
Congresos y Ediciones semFYC
Carrer del Pi, 11, Pl. 2, Of. 13
08002 Barcelona
Tel. 0034 93 317 71 29
e-mail: congresos@semfyc.es